Nuvation Bio Inc. · NYSE:NUVB
Nuvation Bio — Q2 2025 Earnings Presentation
6 slides from Nuvation Bio's earnings presentation, Aug 7, 2025
Slide 1: Q2 2025 Financial Results and Business Update
DRIVEN BY SCIENCE FOCUSED ON LIFE Q2 2025 Financial Results and Business Update August 7, 2025
Slide 2: Forward looking statements
Forward looking statements Certain statements included in this presentation (this “Presentation”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statemen
Slide 3: IBTROZI U.S. Commercial Launch & Pipeline Updates
IBTROZITM U.S. Commercial Launch & Pipeline Updates David Hung, M.D. Founder, President, & Chief Executive Officer 3
Slide 4: Financial & Operating Results
Financial & Operating Results Philippe Sauvage Chief Financial Officer 4
Slide 5: Our strong financial position and operational flexibility will allow us to capitalize on the full potential of IBTROZI
Our strong financial position and operational flexibility will allow us to capitalize on the full potential of IBTROZI Financial Results Commentary: Q2 2025 Results • Total revenue included $1.2 million in net revenue from Item1 Q2 2025 Q2 2024 sales of IBTROZI and $3.6 million of revenue from our c
Slide 6: Q2 2025 Financial Results & Business Update: Q&A
Q2 2025 Financial Results & Business Update: Q&A David Hung, M.D. Philippe Sauvage Founder, President & CEO Chief Financial Officer 6
Nuvation Bio — Q2 2025 Earnings Presentation on 6ix